# Safety and Efficacy of BRM421 for Dry Eye Syndrome Treatment

> **NCT04343287** · PHASE2,PHASE3 · COMPLETED · sponsor: **BRIM Biotechnology Inc.** · enrollment: 220 (actual)

## Conditions studied

- Dry Eye Syndrome

## Interventions

- **DRUG:** BRM421
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04343287
- **Lead sponsor:** BRIM Biotechnology Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-15
- **Primary completion:** 2020-06-23
- **Final completion:** 2020-06-23
- **Target enrollment:** 220 (ACTUAL)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04343287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04343287, "Safety and Efficacy of BRM421 for Dry Eye Syndrome Treatment". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04343287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*